Menu
Search
|

Menu

Close
X

OncoSec Medical Inc ONCS.OQ (NASDAQ Stock Exchange Capital Market)

1.81 USD
-0.14 (-7.18%)
As of Feb 16
chart
Previous Close 1.95
Open 1.96
Volume 747,733
3m Avg Volume 381,341
Today’s High 2.00
Today’s Low 1.81
52 Week High 2.95
52 Week Low 0.88
Shares Outstanding (mil) 21.17
Market Capitalization (mil) 22.01
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.264
FY17
-1.064
FY16
-1.624
FY15
-1.669
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
1.38
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-105.93
14.43
Return on Equity (TTM)
vs sector
-110.71
16.13

EXECUTIVE LEADERSHIP

Avtar Dhillon
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Punit Dhillon
President, Director, Since 2017
Salary: $408,890.00
Bonus: --
Daniel O'Connor
Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Richard Slansky
Chief Financial Officer, Since 2015
Salary: $273,898.00
Bonus: --
Sheela Mohan-Peterson
Chief Legal and Compliance Officer, Since 2015
Salary: $225,966.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

5820 Nancy Ridge Dr
SAN DIEGO   CA   92121-2842

Phone: +1858.2107333
Site: oncosec.com/

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

SPONSORED STORIES